Your browser doesn't support javascript.
loading
Survival outcome of intermediate risk neuroblastoma at Children Cancer Hospital Egypt.
Elzomor, Hossam; Ahmed, Gehad; Elmenawi, Salma; Elkinaai, Naglaa; Refaat, Amal; Soliman, Sonya; Abdelwahab, Mai Amr; Zaghloul, Mohamed Saad; Fawzy, Mohamed.
Afiliação
  • Elzomor H; Pediatric Oncology Department, Children's Cancer Hospital (CCHE), 57357, Egypt; National Cancer Institute, Cairo University, Egypt.
  • Ahmed G; Surgical Oncology Department, CCHE, Egypt; Faculty of Medicine, Helwan University, Egypt.
  • Elmenawi S; Clinical Research Department, CCHE, Egypt. Electronic address: s.menawi@gmail.com.
  • Elkinaai N; Pathology Department, CCHE, Egypt; National Cancer Institute, Cairo University, Egypt.
  • Refaat A; Radiology Department, CCHE, Egypt; National Cancer Institute, Cairo University, Egypt.
  • Soliman S; Clinical Pathology Department, CCHE, Egypt; National Cancer Institute, Cairo University, Egypt.
  • Abdelwahab MA; Nuclear Medicine Department, CCHE, Egypt; National Cancer Institute, Cairo University, Egypt.
  • Zaghloul MS; Radiotherapy Department, CCHE, Egypt; National Cancer Institute, Cairo University, Egypt.
  • Fawzy M; Pediatric Oncology Department, Children's Cancer Hospital (CCHE), 57357, Egypt; National Cancer Institute, Cairo University, Egypt.
J Egypt Natl Canc Inst ; 30(1): 21-26, 2018 Mar.
Article em En | MEDLINE | ID: mdl-29428371
AIM: The study aims to evaluate survival outcome in newly diagnosed pediatric intermediate risk neuroblastoma patients treated at the Children Cancer Hospital - Egypt and their relation to various clinical and pathological factors. METHODS: The study included stage 3 patients <1.5 years, children 1.5 years or older with stage 3 disease and favorable histopathological features, infants (<1 year) with International Neuroblastoma Staging System (INSS) stage 4 disease, stage 4 children 1-1.5 years with favorable biology, and infants stage 4 s (with unfavorable biologic features). Patients received systemic chemotherapy, in the form of etoposide and carboplatin alternating with cyclophosphamide, doxorubicin and vincristine, administered at 3-week intervals, with a total of 6 or 8 cycles guided by reaching objective overall response (complete/very good partial/partial response). RESULTS: The study included 136 patients, 67 males and 69 females. 101 patients had abdominal primary tumors, 28 had mediastinal masss and 7 with masses in the neck; 68% were stage 3 and the remaining (n = 44) had metastatic disease. The three-year overall survival (OS) and event-free survival (EFS) estimates were 94% ±â€¯2% and 90.9% ±â€¯2.5%, respectively. OS and EFS by gender, age, pathology and INPC were all statistically not significantly different. Moreover, OS for patients having surgery versus no surgery (inoperable residual only) was statistically significant (98.4% ±â€¯1.6% & 88.7% ±â€¯5.3%, respectively, p = .034). CONCLUSION: A very high rate of survival is currently achievable in patients with intermediate risk neuroblastoma by chemotherapy or chemotherapy and surgery. In addition to response, our plan is to adopt biologically-based treatment to reduce treatment-induced complications among survivors.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neuroblastoma Tipo de estudo: Diagnostic_studies / Etiology_studies / Risk_factors_studies Limite: Adolescent / Child / Child, preschool / Female / Humans / Infant / Male / Newborn País/Região como assunto: Africa Idioma: En Revista: J Egypt Natl Canc Inst Assunto da revista: NEOPLASIAS Ano de publicação: 2018 Tipo de documento: Article País de afiliação: Egito País de publicação: Reino Unido

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neuroblastoma Tipo de estudo: Diagnostic_studies / Etiology_studies / Risk_factors_studies Limite: Adolescent / Child / Child, preschool / Female / Humans / Infant / Male / Newborn País/Região como assunto: Africa Idioma: En Revista: J Egypt Natl Canc Inst Assunto da revista: NEOPLASIAS Ano de publicação: 2018 Tipo de documento: Article País de afiliação: Egito País de publicação: Reino Unido